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REV IEW ART ICLE
Inflammation-associated remodelling and fibrosis in the lung
– a process and an end point
William A.H. Wallace*, Paul M. Fitch*, A. John Simpson* and Sarah E.M. Howie*
*MRC Centre for Inflammation Research, Queen’s Medical Research Institute, Edinburgh University, Edinburgh, UK; and
Departments of

Pathology and

Respiratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK
Introduction
To pathologists and chest physicians ‘What is pulmonary
fibrosis?’ may seem a straightforward question. Pulmonary
fibrosis is the presence of scarring in the alveolar compart-
ment of the lung where gas exchange occurs. This may be
localized, for example following tuberculous infection
(Dheda et al. 2005), or more diffuse such as in patients with
interstitial lung disease (ILD) (Leslie 2005). Fibrosis can
involve other areas of the lung as well, such as the bronchi
(Vignola et al. 2000) and the pleura (Jantz & Antony 2006),
but in general the unqualified term pulmonary fibrosis
usually indicates alveolar pathology. The presence of symp-
toms will depend on the extent of the process and whether
it is static or progressive. Typically when lung fibrosis is
extensive and diffuse it results in a restrictive ventilatory
defect with hypoxia and in some cases pulmonary hyperten-
sion, cor pulmonale and death (Zisman et al. 2005). More
localized areas of fibrosis may be associated with distortion
of the lung anatomy and secondary conditions such as bron-
chiectasis and chronic respiratory infection (Dheda et al.
2005).
In more recent years the terms ‘lung remodelling’ and
‘fibrosis’ have been used, at times almost interchangeably, to
INTERNATIONAL
JOURNAL OF
EXPERIMENTAL
PATHOLOGY
Received for publication:
16 October 2006
Accepted for publication:
16 October 2006
Correspondence:
Dr William A.H. Wallace
Department of Pathology
Royal Infirmary of Edinburgh
51 Little France Crescent
Edinburgh EH16 4SA
Tel.: 0131 242 7134
Fax: 0131 242 7146
E-mail:
william.wallace@luht.scot.nhs.uk
Summary
Fibrosis by common usage in the pathological and clinical literature is the end result
of a healing process and synonymous with scarring. We would argue that its use to
describe a dynamic series of events which may be reversible is unhelpful and that the
term ‘lung remodelling’ is a better description for this process as it reflects changes
in tissue organization that may or may not progress to ‘fibrosis’ as a final fixed
point. Resolution, through reversal of active lung remodelling, by therapeutic inter-
vention is possible providing the alveolar architecture remains intact. If the lung
architecture is lost then healing by permanent fibrosis with loss of organ function is
inevitable.
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describe a range of processes in the lung where the architec-
ture is altered up to, and including, the formation of perma-
nent, fixed scar tissue. Some authors, however, suggest that
‘fibrosis’ is, or could be reversible (Marshall et al. 1998;
Bellingan 2002; Lawson et al. 2005). This clearly is a differ-
ent view of ‘fibrosis’ from the traditional clinico-pathological
understanding of the term. This article aims, in the context
of human lung disease, at considering various scenarios
where the lung’s response to inflammation is associated with
different outcomes (Figure 1). We hope to convince the rea-
der that the use of the term ‘fibrosis’ in the context of
inflammation-associated lung injury should define one poss-
ible outcome of the repair process which is characterized by
the replacement of pre-existing alveolar structure by perma-
nent fixed scar tissue. As such it should be regarded as syn-
onymous with scar tissue. We suggest that the term ‘lung
remodelling’ should be used as a descriptor for the dynamic
repair multi-step process that occurs in the lung following
inflammatory injury. This process may either be reversible
with resolution and return to the pre-existing structure, or
progress to the point of irreversible fixed fibrosis.
In order to understand what is occurring at the tissue level
in the lung and what factors might dictate whether or not
an inflammatory process is likely to lead to permanent fixed
fibrosis or a more labile potentially reversible form of
remodelling it is useful to look at different patterns of lung
injury and outcome. Before this, however, it is necessary to
consider the structure of the normal alveoli (reviewed by
Hasleton & Curry 1996; Travis et al. 2002a). These are
arranged in functional groups termed ‘acinar units’ which
are all supplied by a single respiratory bronchiole and resem-
ble a bunch of grapes at the end of a stalk. The alveoli are
predominantly lined by thin attenuated type I epithelial cells
which sit on a basement membrane. Within the alveolar wall
are capillary loops lined by endothelial cells. They too have
a basement membrane that is extensively fused to the base-
ment membrane of the alveolar epithelial cells. Also within
the alveolar wall is a supporting network of collagen and
elastic fibres that in effect forms the supporting skeleton of
the lung with scattered resident fibroblasts and tissue macr-
ophages.
Acute inflammation and alveolar injury
It is well established that the lung can be subjected to
intense inflammatory reactions and return to its pre-inflam-
matory state. Bacterial pneumonia with organisms such as
Streptococcus pneumoniae cause an intense acute inflamma-
tory process in the lung with the alveolar spaces becoming
filled with neutrophils admixed with a fibrinous exudate
(reviewed by Macfarlane 1995; Travis et al. 2002b). Provi-
ding the patient survives the acute septic episode the lung
returns to its previous state with no significant fibrosis or
alteration in the pre-existing architecture (Macfarlane 1995).
We would term this type of repair ‘resolution’.
Animal models indicate that there is damage to the alveo-
lar epithelium in acute pneumonia (McElroy et al. 1995)
and a key factor in allowing the desirable outcome of resolu-
tion in such a setting is that the triggering agents, in this
case the bacteria, are rapidly cleared (Clegg et al. 2005).
Ultrastructural studies in animal models show that the base-
ment membrane is retained and undamaged (McElroy et al.
1995) allowing rapid re-epithelialization to occur (Clegg
et al. 2005) and we know from studies in animals that this
inhibits the proliferation of mesenchymal cells (Adamson
et al. 1988, 1990).
We would suggest therefore that the desirable outcome of
resolution in acute pneumococcal pneumonia occurs because
the inflammatory reaction is very limited in duration and
there is no chronic inflammation or ongoing lung injury. In
contrast, infections with organisms associated with a sus-
tained chronic inflammation, such as tuberculosis, where
there is ongoing tissue injury are not associated with resolu-
tion but result in remodelling and fibrosis (Dheda et al.
2005).
Chronic inflammation and alveolar injury
Chronic inflammation by definition is associated with, or
will result in, tissue damage and inevitably this is associated
with attempts by the tissue to repair itself (Kumar et al.
2005a). In most instances, especially if the chronic inflam-
matory process is ongoing the tissue damage and repair will
be seen occurring in tandem. The traditional pathological
perspective is that scarring, or fibrosis, is the end result of
damage in a tissue not capable of regeneration and is fixed
with no possibility of a return to the pre-existing structure
(Kumar et al. 2005b). Chronic inflammation in the alveolar
compartment of the lung can be associated with a wide
range of aetiologies: infection (bacterial, mycobacterial, viral
and atypical agents such as mycoplasma) (Travis et al.
2002b), systemic immunological processes (such as systemic
sclerosis) (Nicholson et al. 2002a; Crestani 2005), allergic
processes (such as hypersensitivity pneumonitis) (Mohr
2004), toxins (including drugs) (Kehrer & Kocew 1985;
Camus et al. 2004), dusts (Glazer & Newman 2004) and
radiation (Camus et al. 2004), although in many clinical
situations the aetiology remains unknown (Leslie 2005).
The lung’s response to such a diverse range of potentially
damaging agents is relatively limited and as such similar
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Figure 1 Schematic representation of possible outcomes following inflammation-associated lung injury with clinical examples. (a) Photo-
micrograph of acute bacterial pneumonia showing alveolar filling by neutrophils and fibrin. (b) Photomicrograph of cryptogenic organizing
pneumonia showing the nodular buds of organizing exudates in airspaces. (c) Photomicrograph of usual interstitial pneumonitis showing
extensive fibrosis with loss of the pre-existing alveolar architecture. ecm, extracellular matrix; COP, cryptogenic organizing pneumonia;
HP, hypersensitivity pneumonitis; ARDS, adult respiratory distress syndrome; UIP, usual interstitial pneumonitis; TB, tuberculosis.
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patterns of response may be seen clinically and pathologic-
ally in patients with differing aetiologies (Nicholson 2002b).
It is also important to appreciate that while an external sti-
mulus may trigger chronic inflammation, once this is initi-
ated the inflammatory process itself may result in further
‘by-stander’ tissue damage. An example of this would be the
florid type IV hypersensitivity reaction that characterizes
post primary tuberculous infection (Dheda et al. 2005).
Ideally tissue injury would be associated with a healing
process that resulted in restoration of the pre-existing struc-
ture. While this may occur in some tissues such as bone
(Gerstenfeld et al. 2003) and liver (Taub 2004) most tissues,
including the lung, are not capable of organ regeneration
and tissue damage leads to repair characterized by the for-
mation of scar tissue (Kumar et al. 2005b).
Tissue injury at the alveolar level associated with chronic
inflammation could have a variety of potential outcomes.
There could be injury and loss of the alveolar epithelial cells,
damage or loss of the basement membrane, endothelial cell
loss/injury and at the most severe end of the spectrum a
complete collapse of the collagen and elastic support frame-
work of the alveoli. The exact ultra-structural patterns of
injury may depend on the nature of the insult. Systemically
mediated lung injury may be more associated with endothel-
ial injury (Fujita et al. 1998), although necrosis appears to
be unusual (Hasleton 1996; Menezes et al. 2005). Direct
pulmonary insults may show more prominent epithelial
injury (Menezes et al. 2005). The common effect, however,
would appear to be that a protein-rich exudate leaks out
into the alveolar space and this is associated with migration
of myofibroblasts from the interstitium resulting in the for-
mation of organizing immature collagenous tissue (Chau
et al. 2005).
If the stimulus for the chronic inflammatory process is
removed and the basement membrane, collagen and elastic
structure of the alveolus remains intact re-epithelialization
could still theoretically occur in tandem with removal of the
immature intra-lumenal collagenous tissue in the lumen by
the fibrinolytic system (Idell 2003) and apoptosis of the
myofibroblasts (Kuwano et al. 2004) (resolution). Alternat-
ively, either because of persistence of the chronic inflamma-
tory process or the severity of the tissue damage, there could
be loss of tissue integrity and alveolar collapse or even com-
plete destruction.
This is clearly seen in patients with localized destructive
processes such as necrotizing pneumonias (Travis et al.
2002b), type IV hypersensitivity reactions with mycobacteri-
al infection (Dheda et al. 2005) and pulmonary infarcts
(Corrin 2000) where by definition there is extensive loss of
tissue. This situation by necessity precludes any return to the
pre-existing tissue architecture. There would be organization
of the immature fibrinous exudate with neovascularization,
proliferation of myofibroblasts, deposition of increasing
amounts of extracellular matrix components and the devel-
opment of scarring (Kumar et al. 2005b) which, depending
on the pattern of injury, could be localized or diffuse and, in
the case of continuing chronic inflammation, progressive
(fibrosis).
Remodelling in interstitial lung disease
The ILDs represent a group of lung conditions characterized
by inflammation and remodelling of the alveolar compart-
ment of the lung (Leslie 2005) that help to illustrate some of
these potential consequences of inflammatory-associated
lung injury. In most instances the aetiology of this group of
conditions is unclear but it is apparent that a wide range of
triggering events appear to give rise to a very limited and
rather stereotyped pattern of reaction in the tissue
(Nicholson 2002b). At least in the case of idiopathic ILD,
clinical progress and prognosis is closely related to the histo-
logical pattern (Monaghan et al. 2004; Tansey et al. 2004).
Examination of some of these patterns of lung disease pro-
vides some support for our hypothesis that resolution of a
chronic inflammatory-associated lung injury without perma-
nent fibrosis may be dependent on the nature of injury to
the lung structure induced either by the injurious agent itself
or the chronic inflammation.
Idiopathic pulmonary fibrosis (IPF) is the commonest clin-
ical form of ILD. The typical pattern of lung pathology asso-
ciated with this is usual interstitial pneumonia (UIP). IPF has
a very poor prognosis and no pharmacological intervention
has been shown to alter this (Walter et al. 2006). The patho-
genesis is unclear but it appears associated with an acute on
chronic interstitial inflammatory process in the distal lung
(Campbell et al. 1985; Leslie 2005) with evidence of type I
alveolar epithelial cell injury (Corrin et al. 1985). This is
associated with foci of organizing exudates, identifiable as
‘fibroblastic foci’, composed of myofibroblasts and rather
loose oedematous extracellular matrix (Nicholson 2002b).
These fibroblastic foci are believed to be the sites of active
remodelling with deposition of matrix proteins (Wallace
et al. 1995). Morphological studies suggest that these repre-
sent foci of epithelial injury and subsequent alveolar collapse
(Myers & Katzenstein 1988a). Although this is less gross
than in the examples of necrotizing pneumonia, mycobacter-
ial infection or infarction discussed above, the ultimate effect
is the same. The loss of the normal alveolar structure pre-
cludes resolution and commits the lung to healing by fibro-
sis. From what we have suggested before, given that UIP is
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characterized by ongoing inflammation, injury and architec-
tural collapse, it would be unsurprising that the condition is
progressive and associated with extensive lung scarring lead-
ing to the clinical features that a clinician would recognize
as pulmonary fibrosis.
In contrast to UIP, cryptogenic organizing pneumonia
(COP) is another pattern of ILD with a wide range of poten-
tial aetiologies characterized by interstitial inflammation and
the formation of intralumenal buds of organizing exudates
composed of myofibroblasts and loose myxoid stroma
(Nicholson 2002b; Cordier 2004). Morphologically the
appearance of these buds is not dissimilar to that of the
organizing fibroblastic foci described above in UIP. Despite
this, the clinical progress of the disease is completely differ-
ent and resolution is usually seen with steroid therapy. In
the majority of cases the lung returns to its previous archi-
tecture rather than becoming fibrotic, although in a minority
of cases this may occur (Schlessinger & Koss 2005). At the
ultrastructural level in COP there is alveolar epithelial injury
but the alveolar structure appears to be retained rather than
collapsing (Myers & Katzenstein 1988b). This preservation
of the alveolar architecture may therefore account for the
ability of this pattern of injury to undergo resolution rather
than fibrosis.
Given the hypothesis we are putting forward it would
seem possible that a chronic inflammatory condition could
result in a pattern of lung injury where the alveolar architec-
ture was retained and therefore potentially capable of reso-
lution. If the lung injury then became more severe it could
result in either localized or more diffuse damage to the
alveolar architecture of the lung resulting in areas where
healing by fibrosis becomes inevitable. This may be the case
in diffuse alveolar damage syndrome, a pattern of lung
injury associated with the adult respiratory distress syn-
drome (ARDS) (Nicholson 2002b).
The ARDS can result from direct lung injury (for example
with pneumonia, inhalation of gases or aspiration) or indi-
rect injury (for example from systemic sepsis or in associ-
ation with pancreatitis or extrapulmonary trauma) (Hudson
et al. 1995). The early histological features are of oedema
with leakage of fibrin-rich fluid into the alveolar spaces.
After 48–72 h this material starts to form immature plugs of
organizing exudates in the airspaces, termed the fibro-prolif-
erative phase, with myofibroblasts and loose immature oede-
matous stroma (Wallace & Donnelly 2002). Many patients
develop extensive pulmonary fibrosis with replacement of
the normal alveolar architecture by collagenous tissue
(Bellingan 2002). Some patients who survive may be left
with evidence of variable pulmonary fibrosis but a small
number appear to develop severe ARDS that resolves
(Bellingan 2002). The mechanisms regulating the outcome of
the fibro-proliferative phase are unclear but we would sug-
gest that collapse of the alveolar structure of the lung would
be one event whereby fibrosis, rather than resolution,
becomes an inevitable outcome. Some ultrastructural studies
have certainly indicated that alveolar collapse does occur in
some patients with ARDS (Hoelz et al. 2001). A similar
mechanism might be applicable in other conditions such as
hypersensitivity pneumonitis, where acute exposures to the
triggering agent may not result in scarring whereas chronic
exposures may lead to extensive pulmonary fibrosis (Travis
et al. 2002c).
Up until this point we have argued that in situations
where the structural integrity of the tissue is retained there is
a capacity for the tissue to return to its pre-existing architec-
ture. However, there are conditions where the alveolar
architecture appears to be largely retained but there is evi-
dence of progressive scarring. As discussed above most
patients with idiopathic ILD have a histological pattern of
lung injury that we recognize as UIP. A group of patients
with idiopathic ILD have, however, been recognized in the
last few years to have a different pattern of disease termed
non-specific interstitial pneumonia (NSIP) (Katzenstein &
Myers 2000). Histologically this is characterized by a rela-
tively diffuse and even inflammatory or fibrous expansion of
the alveolar walls but with the architecture retained
(Figure 2). The process is described as temporally homogen-
eous and areas of immature fibroblastic tissue are not identi-
fiable (Katzenstein & Myers 2000; Nicholson 2002b). These
patients in general have a better prognosis than those with
Figure 2 Photomicrograph of a biopsy showing the typical even
pattern with fibrous expansion of alveolar walls typical of non-
specific interstitial pneumonia. No histological evidence of
organizing intra-lumenal exudates is identifiable (haematoxylin
and eosin, original magnification ·100).
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idiopathic UIP (Daniil et al. 1999). The pathogenesis of
NSIP is uncertain but morphologically it appears that fibrous
tissue is laid down progressively and uniformly on the pre-
existing alveolar structures. There is typically marked type II
alveolar epithelial cell proliferation but no histological fea-
tures suggesting organizing exudates within the alveoli
(Katzenstein & Myers 2000; Nicholson 2002b). One poss-
ible explanation could be that this is evidence of a true
‘interstitial fibrosis’ with the process being limited to within
the alveolar walls rather than representing fibrosis created
by organizing fibrinous material which has leaked into the
airspaces as described above.
Interpretation of results in animal models of
lung fibrosis
Over the last 30 years or so a wide range of animal models
have been developed to study the processes of chronic
inflammation and repair in the lung. The majority of these,
induced by, for example, bleomycin (Thrall & Scalise 1995)
and silica (Lemaire 1995) are what can be termed toxic
models that generate inflammation and lung damage.
Intra-tracheal bleomycin is perhaps the most widely used
model for studying ‘fibrosis’ in the lung (Thrall & Scalise
1995; Chau et al. 2005). This model produces intense lung
injury with an inflammatory infiltrate in the lung, leak of
proteinaceous fluid into the airspaces and organization with
the ultimate development of focal established fibrosis. This
is principally seen around the airways and variably in the
peripheral lung (Thrall & Scalise 1995; Chau et al. 2005).
Studies appear to suggest that permanent fixed fibrous
tissue becomes established between day 14 and 21 after
exposure (Izbicki et al. 2002). This established fixed fibrosis
is, however, much more localized than the inflammation/
organization seen at earlier time points. Studies using inter-
ventions in such models may modulate lung injury and
organization but not necessarily lung ‘fibrosis’, unless suffi-
ciently late time points are included. This is not to suggest
that these models cannot give us useful information on the
regulatory process of lung injury but it could be misleading
to suggest that they can show amelioration or prevention
of ‘lung fibrosis’ unless appropriate studies at late time
points are included after the remodelling process is finally
complete.
What are we aiming to treat – remodelling or
fibrosis?
One of the current major objectives behind research into
‘fibrotic’ lung disease whether clinically or in animal models
is the search for new therapeutic strategies and pharmacolo-
gical agents. Much of this is clearly aimed at modulating the
remodelling that occurs with inflammation and injury in the
lung. Such approaches could be thought of as either prevent-
ing the development of fibrosis by promoting complete reso-
lution of the remodelling process or in the more common
clinical situation preventing progression and the develop-
ment of further fibrosis.
This inevitably raises the question over whether ‘fibrosis’
is reversible. It is at this point that the need for clear, unam-
biguous terminology becomes apparent. Do we mean ‘pre-
venting or reversing the dynamic remodelling fibro-
proliferative/remodelling process’ or actually ‘replacing
established fibrotic lung tissue with new functioning alveo-
lated lung’? From the discussion above the first goal is
potentially achievable by therapeutic intervention but the
second would require extremely complex targeted tissue
engineering to recreate alveoli whose structure has been lost
and replaced by the fibrosis. Such potential confusion indi-
cates the need for consistency and clarity in the terminology
used by pathologists, physicians, radiologists and scientists
working in the field, especially given the ready access that
patients now have to the medical and scientific literature.
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